Conditions: Infection, Human Immunodeficiency Virus
Keywords: HIV naive Phase II integrase inhibitor GSK1265744 newly diagnosed pharmacokinetics AIDS integrase HIV Infections Treatment naive
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 9
Healthy volunteers: no

Brief summary:
The purpose of this randomized, double-blinded study is to test the safety of GSK1265744 and how well it works on reducing the amount of HIV in the blood. It will also look at how people react to and how a human body uses GSK1265744. This study will compare the effects of GSK1265744 and placebo.

The study will consist of 1 or 2 parts to look at doses of GSK1265744. About 8 people will take part in Part 1 of the study receiving dose A. If additional dosing information is needed after Part 1, about 6 people will take part in Part 2 of the study receiving dose B.

Detailed description:

Arms:
arm 1: GSK1265744 30 mg arm 2: Placebo to match GSK1265744 arm 3: GSK1265744 5 mg

Interventions: intervention 1: GSK1265744 30mg intervention 2: Placebo intervention 3: GSK1265744 5mg
Intervention descriptions: intervention 1: GSK1265744 30 mg intervention 2: Placebo to match GSK1265744 intervention 3: GSK1265744 5mg

Protocol document: